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CHAPTER -I 
INTRODUCTION 
 
1.1 BACKGROUND 
Tuberculosis related deaths are rising in the world in an alarming trend. 
No wonder that this chronic infection is setting the major brakes in human 
resources and economy of a nation particularly the developing ones. Also the 
mortality in HIV due to TB is increasing and reported 36 million deaths 
worldwide in 2013.  
The main reasons for this high mortality are because of lack of proper 
diagnosis in the apt time. This is particularly important in patients with HIV 
and TB co infection and extra pulmonary TB in special because the detection 
rates are low.(5,6) There is an urgent need to implement newer diagnostic 
modalities for detection of TB especially in highly HIV prevalent areas. 
The diagnostic gold standard for tuberculosis detection is culture. But it 
takes longer time and cannot be relied for the implementation of immediate 
active treatment when compared to microscopy, especially with the Fluorescent 
LED microscopy which is a quick method of identification.(12,16) 
For the detection of TB using microscopy, the sensitivity is an issue and 
that’s addressed partly by the implementation of CB NAAT in 2010 by WHO 
in HIV patients for the detection of TB. 
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In this study we are analyzing the role of LED microscopy and 
CBNAAT in detection of patients suspecting pulmonary and extra pulmonary 
TB in HIV positive patients and HIV negative patients.  
Recent years witnessed rapid advances in embracement of newer 
technologies in the field of diagnosis of tuberculosis as well as the detection of 
drug resistant PTB. The Xpert MTB/RIF assay, which enables detection 
of Mycobacterium Tuberculosis(MTB) and Rifampicin (RIF) resistance was 
endorsed by WHO in December 2010. This test was specifically recommended 
for the initial diagnostic test for suspected drug-resistant and HIV-associated 
pulmonary tuberculosis. 
Accurate point of care diagnostic test should be the one or a 
combination of some, which are affordable to the nation as well as able to 
detect the burden of tuberculosis with good sensitivity and specificity without 
compromising the time delay in diagnosis and hence treatment. Here the main 
comparison is between the LED fluorescence microscopy technique and CB 
NAAT. 
 
1.2 AIMS AND OBJECTIVES 
1. To compare the yield of detection of Pulmonary and Extra Pulmonary 
Tuberculosis inZeil Neilson smear negative patients with HIV infection 
by CBNAAT and fluorescent LED microscopy. 
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2. To compare the detection of pulmonary and extra pulmonary 
tuberculosis by LED fluorescent microscopy and CBNAAT in HIV 
negative patients. 
3. To assess the difference in HIV positive patients and HIV negative 
patients of tuberculosis with CBNAAT and fluorescent LED 
microscopy. 
4. To determine if there is any CD4 count co relation among PLWHA in 
terms of detection with these two techniques. 
 
1.3 INCLUSION CRITERIA 
1. PLWHA suspecting pulmonary TB with negative ZN smear test, 
positive chest X-ray findings. 
2. PLWHA suspected with tuberculous lymphadenitis , tuberculous pleural 
effusion with negative ZN smear test. 
3. HIV negative patients suspecting pulmonary TB, lymph node TB, or 
tuberculous pleural effusion with negative ZN smear test. 
 
1.4 EXCLUSION CRITERIA 
1. Patients suspecting pulmonary TB with normal chest X-ray  
2. Patients in whom ZN smear test was positive 
3. Patients with past history of TB, already taken ATT 
4. All diabetes mellitus patients. 
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CHAPTER -II 
MATERIALS AND METHODS 
 
This study was conducted in K.A.P.V Govt. Medical College, Trichy, 
January2015-April 2016. The patients who were suspecting tuberculosis were 
selected from HIV positive patients and HIV negative patients. Patients with 
pulmonary symptoms of cough of more than 1 week with weight loss or loss of 
appetite, night sweats etc. were subjected to chest X-ray and those with chest x-
ray findings suggestive of tuberculosis or consolidation were selected for the 
study. Also the patients with these symptoms and pleural effusion or lymph 
node positivity were also selected. All diabetes mellitus patients were excluded 
from the study. 
Based on these 40 patients suspecting pulmonary TB were selected with 
chest X-ray findings. Two early morning sputum samples were sent to 
microbiology laboratory in sterile containers. These were subjected to 
examination for AFB using Zeil Neelson staining and detection with LIGHT 
MICROSCOPY,FLUORESCENT LED MICROSCOPY and also CB NAAT 
technique for nucleic acid amplification and identification of MTB. 
Smears for LED ﬂuorescent microscopy were prepared following 
standard procedures of preparation of slides, and staining with Auramine .All 
specimens were concentrated by cytocentrifugation. All smears reported as 
“scanty” acid-fast bacilli (AFB) by LED ﬂuorescent microscopy were 
considered as positive results for performing the analysis of the study. Sample 
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preparation and Xpert MTB/RIF procedure were performed by trained 
operators as described previously [2,17].Statistical analysis was performed 
using SPSS software, version 20. 
 The study was approved by the Ethical Committee of the K.A.P.V Govt. 
Medical College, Trichy Institutional Review Board. 
The results were given as AFB negative,1+,2+,3+,4+ and CB NAAT 
negative, high, medium, low, very low. All ZN smear test positive patients 
were excluded from the study. 
Similarly, the matted lymph nodes were subjected to FNAC and send for 
analysis using these 2 methods, also 10 patients of suspected tuberculous 
pleural effusion were selected and pleural fluid were send for analysis with 
LED fluorescent microscopy and CB NAAT and results were analyzed. 
CD4 count of all the patients with HIV positivity were noted at the time 
of detection of tuberculosis and analyzed if it has any co relation with these 
results. Results were analyzed statistically with SPSS software, version 20. 
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CHAPTER - III 
REVIEW OF LITERATURE 
 
Tuberculosis is an age old infection caused by Mycobacterium 
Tuberculosis complex. It is thought to be emerged 70,000 years back in Africa, 
and expanded to modern worlds then onwards.(8).This disease most commonly 
affects the lungs in two third of the patient, but involves almost all of the organ 
systems in body and the systems other than lungs are involved in one third of 
the patients. 
The public health importance of this disease is that when it is drug 
susceptible and treated properly, curable in majority of patients and if left 
untreated fatal in 50-60% of patients within 5 years.(8) 
 
3.1 EPIDEMIOLOGY 
In 2013, 5.7 million new TB cases were reported worldwide to WHO. 
Out of which 95 percent was from the developing countries. But this is 
considered as around 2/3
rd
 of total new cases as the infections are under 
diagnosed in the developing countries because of poor resources in detection as 
well as socio economic, cultural reasons prevailing mostly in the developing 
countries. . Based on this, the estimated total new TB cases worldwide by 
WHO 2013 was 9 million. 
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 Of the newly diagnosed total TB cases by WHO in 2013, 13% were HIV 
associated. And the mortality was also high in this group of patients. A total of 
0.36 million out of Out of 1.49 million new patients 0.36 million patients were 
died in 2013 because of tuberculosis.(8). 
Coming to the matter of drug resistance, about 28% of the total cases of 
tuberculosis were drug resistant. 
 
3.2 ETIOLOGICAL AGENT 
Mycobacterium Tuberculosis, is a spore forming and rod shaped 
bacteria, 0.5-3-micronlength. This is a gram negative, but acid fast positive 
bacteria because of high content of mycolic acids, other long chain fatty acids 
and lipids. 
Some other microorganisms also display some acid fastness. These 
include species of Noccardia, Rhodococcus, Legionella micdadei, and the 
protozoa Isospora & Cryptosporidium. In the cell wall of mycobacteria, lipids 
like mycolic acids are linked to underlying arabinogalactan and peptidoglycan 
molecules. Because of this particular structure, there is very low permeability 
of the cell wall to the anti-bacterial agents. 
           Yet another molecule in the cell wall of mycobacteria, 
lipoarabinomannan, is involved in the interaction between bacteria and host 
cells, resulting in the increased survival of Mycobacterium tuberculosis inside 
the macrophages.  
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The genome sequence of Mycobacterium tuberculosis consists of 4043 
genes encoding 3993 proteins and fifty genes encoding RNAs. There is a high 
guanine and cytosine concentration (65.5%). This indicates the aerobic lifestyle 
of organism. This explains the upper lobe preference in pulmonary 
tuberculosis. A large proportion of genes are devoted to the production of 
enzymes involved in cell wall metabolism. 
 
3.3 MODE OF TRANSMISSION 
The transmission of infection is via aerosolized particles from 
respiratory tract when the patient coughs. These particles are less than 5-10 
microns in diameter. These remain suspended in the atmosphere for several 
hours, and there are approximately 3000 such particles in one cough. On an 
average, a person may transmit infection to 20 contacts before being 
recognized as a patient. Transmission through skin or placenta are uncommon 
and not of much significance. 
 
3.4 RISK FACTORS FOR ACTIVE ILLNESS 
1. Recent infection with Mycobacterium tuberculosis 
2. Fibrotic lesions, silicosis. 
3. HIV co-infection 
4. CKD on dialysis 
5. Diabetes mellitus 
6. Smoking 
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7. IV drug abuse, immune suppressive treatment 
8. Malnutrition and underweight. 
Among these the highest odd’s ratio is for HIV infection. 
The relation with age is that, the adolescent and early adulthood age 
groups are particularly more prone for active infection because of unknown 
reasons. In female, clusters in 25-34 years of age and there is a rise of active 
disease in elderly because of waning immunity. 
 
3.5 NATURAL HISTORY 
 One third of PTB died within 1 year(8) 
 More than 50% died within 5 years 
 5-year mortality rate among sputum positive PTB 65% 
 
3.6 PATHOGENESIS AND IMMUNITY(9) 
The infection with Mycobacterium tuberculosis begins with the 
inhalation of droplet nuclei containing large amount of mycobacteria, released 
when an infectious patients coughs and when they are taken up by inhalation 
by a close by stander... The majority of inhaled bacteria are trapped in the 
upper airway tract and are expelled by ciliated mucosal cells. But a small 
fraction (usually less than10%) will reach the alveoli.  Alveoli have a unique 
immunoregulatory environment. The pulmonary alveolar macrophages, which 
are the key immunoregulatory cell in alveoli, have not yet been activated to 
phagocytose the bacteria. 
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The adhesion of TB mycobacteria to macrophages results  from binding 
of the bacterial cell wall to a large variety of  cell-surface molecules expressed 
over the macrophages, including complement receptors, the mannose  receptor, 
the immunoglobulin receptors, and some scavenger receptors. 
The complement activation enhances the phagocytosis. After 
phagocytosis, TB bacteria will get captured into the lysosomes to form 
endosomes. They will cause endosomal manipulations, i.e. maturation arrest, 
lack of acid pH and ineffective phagolysosome formation. Because of these, 
they multiply inside the phagosomes  such as phagosome lysosome fusion and 
inflammatory cytokine production. 
After  phagosome formation, the survival of Mycobacterium 
Tuberculosis seems to be dependend on reduced acidification. This results in a 
lack of assembly of a complete vesicular proton adenosine triphosphates. 
A series of complex events are generated by the bacterial cell wall 
lipoglycanlipoarabinomannan (ManLAM). This inhibits the intracellular 
release of calcium. By this the Calcium Calmodulin pathway is impaired, and 
the TB bacteria survive within the phagosomes.  
The phagosome is found to inhibit the production of phosphatidyl 
inositol 3 phosphate (PIP3). PIP3 causes membrane maturation and sorting in 
phagosomes, thereby the phagolysosome formation which would destroy the 
bacteria. If the bacilli successfully in arrest phagosome maturation, then the 
replication begins. Eventually the macrophage ruptures and releases its 
bacillary contents. Other uninfected macrophages are then recruited and the 
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infection cycle continues, ingesting dying macrophages and their bacillary 
content, thus in turn becoming infected themselves and expanding the 
infection. 
After 3 weeks of initial infection, processed TB bacterial antigens reach 
the draining lymph nodes, and are presented by dendritic cells via MHCII to 
CD4 T cells. The IL 12 secreted by macrophages causes proliferation of CD4 T 
cells of Th-1 variety, and they secrete IFN-Gamma. 
Interferon gamma causes macrophage activation-TNF secretion. 
Monocyte differentiation to epithelioid histolytic and granulomatous reaction. 
Also iNOS is activated, NO acts as powerful oxidizer and release of reactive 
free radicals Nitrogen and Oxygen species. 
 
3.7 CLINICAL MANIFESTATIONS 
Pulmonary TB manifestations are broadly divided as pulmonary and 
extra pulmonary. Pulmonary tuberculous diseases are categorized as primary 
and post primary. Primary TB occurs after the initial infection, affects mainly 
children, infectivity is low, cavitations and permanent sequale are rare and 
affects middle and lower lung zones. 
Post primary/adult type affects mostly the apical and posterior segments, 
and runs a chronic debilitating course. 
Extra pulmonary TB mostly manifests in lymph nodes, pleura, genital 
and urinary tract, joints and bones, meninges, peritoneum and pericardium. 
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Lymph node disease manifest as painless matted nodes mostly in posterior 
cervical region. Associated pulmonary tuberculosis is present in less than 50% 
of patients. Lymph node tuberculosis is particularly frequent among children 
and HIV infected patients.  Earlier, the tuberculous lymphadenitis was mostly 
caused by Mycobacterium bovid, but now its caused mostly by Mycobacterium 
tuberculosis.  
            The most common sites for tuberculous lymphadenopathy is posterior 
cervical group and supraclavicular groups. The painless swelling of lymph 
nodes in these regions were historically referred as scrofula. 
In early disease lymph nodes are discrete and over the time they 
progress to matted nodes. On passage of time, they may develop fistulous tracts 
with discharge of caseous material. The systemic symptoms are usually 
uncommon, but present in HIV individuals 
 The diagnosis in tuberculous lymphadenopaphy can be established by 
fine-needle aspiration biopsy(FNAB) or surgical excision biopsy. The yield by 
fine needle aspiration is around 80 %, detection and with culture also yields 
around 90%, 
Lymph node involvement in HIV-TB, they have less organized 
granulomas, so more chance of detection by microscopy and culture. 
20% of patients, there is pleural involvement. It’s mostly due to 
hypersensitivity reactions to the TB microbial antigens or sometimes 
contiguous spread. Associated parenchymal lesions are seen in less than one 
third of patients. Pleural fluid CB NAAT is not generally recommended 
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because of low sensitivity. Pleural biopsy is the preferred method of 
investigation. 
Isolated pleural effusions are usually due to primary infection and 
hypersensitivity reaction to mycobacterial antigens. Post primary infections 
may result in contiguous spread if pleurisy is present. 
Depending up on the extent of reactivation, the effusion can be small, 
and resolve spontaneously. It may be sometimes large to cause symptoms like 
fever, pleuritic chest pain, and breathlessness. Physical examination reveals 
dullness to percussion and absence of breath sounds. A chest X ray reveals the 
effusion. In about one-third of cases, shows a parenchymal lesion.  
Pleural fluid aspiration and analysis is essential for reaching the 
diagnosis. Mostly the fluid is straw colored, and sometimes hemorrhagic. The 
nature of fluid is exudative with protein concentration of more than 50% of  in 
serum. There will be normal to low concentration of glucose. pH will be 
normal to acidic, around 7.3. Total leukocyte count is usually 500–6000/µL). In 
early stages neutrophils are predominant, and in late stages lymphocytes are 
more predominant. 
AFB are rarely seen on  smear, and cultures often may be false negative 
sometimes. Determination  of adenosinedeaminase (ADA) in pleural fluid may 
be a useful screening test. If the value is too low TB may be excluded.  
Measurement of IFN-γ can be helpful. These are done either directly or 
through stimulation of T cells sensitized with mycobacterial antigens. Pleural 
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biopsy is recommended over pleural fluid it reveals granulomas and/or yields a 
positive culture 
Genito urinary TB accounts for  10-15% of total tuberculous patients, 
and 75% will be having pulmonary involvement. Local symptoms like 
nocturnal, dysuria, frequency predominates. Routine urine investigations reveal 
pyuria, hematuria, and culture negative UTI. Lower urinary tract TB can 
progress to pyelonephritis, in kidneys etc. Genital TB is more common in 
females and affects fallopian tubes, endometrium more commonly resulting in 
infertility and abnormal menstrual bleeds. In males mostly present as 
epididimoorchids, Bones and joints tuberculosis is about 10%. 
CNS involvement is for about 5% of patients. Usually in younger age 
group’s culture is the gold standard, detects up to 80%, but CB-NAAT also has 
a similar detection rate. 
Gastrointestinal TB is rare-3.5%. It more commonly involves terminal 
ileum and cecum and peritoneum. In TB peritonitis, yield by direct smear and 
culture of fluid is low. Peritoneal biopsy should be considered for detection. 
 
3.8 HIV ASSOCIATED TUBERCULOSIS 
Tuberculosis is the most common disease affecting HIV patients. Certain 
data highlighting the role of importance of HIV TB co infections are given 
below.(8) 
 Tuberculosis is responsible for about 24% of all-cause mortality in HIV 
patients. 
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 In patients positive for Tuberculin sensitivity test (TST), the annual risk 
for tuberculosis is 3-13%. 
 Evolution of active tuberculosis is faster in patients with HIV, rather in a 
few weeks as opposed to months to years in general population. 
 When Cell mediated immunity(CMI) is only partly affected, pulmonary 
TB is manifested as in immune patients, that is with infiltrates and 
cavities and less lymph node enlargements, where as if severely 
affected, there will be diffuse infiltrates without cavitation is seen and 
there will be more lymph node enlargements, the disease more or less 
resembles primary tuberculosis. 
 Sputum smears are less frequently positive among HIV-TB co 
infections, so that there is a diagnostic challenge for these patients. 
 Incidence of extra pulmonary tuberculosis is higher than the normal 
population, constituting about 40-60% of the cases. 
 It is now recommended that the Xpert MTB/RIF assay should be used 
for the diagnosis of TB in HIV, not the microscopy and treatment should 
not be delayed if Expert MTB/RIF assay is positive. But culture is the 
gold standard test. 
 Yet another important consideration is the Immune reconstitution 
inflammatory syndrome (IRIS). This occurs in the HIV-TB co infected 
patients if we are starting ART first because of undiagnosed TB. When 
effective ART is implemented, cell mediated immunity of the patient 
improves and there is a large cytokine release to the tubercle bacilli, 
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which will cause flare-up of symptoms and signs like lymphadenopathy, 
respiratory symptoms or chest X raymanifestations. Lower baseline CD4 
count and earlier starting of ART are the main risk factors. This is one of 
the reason why we have to rely upon a method of higher diagnostic yield 
to detect TB in HIV rather than the conventional methods. 
 HIV patients with culture positive or AFB positive TB may present with 
normal chest radiograph. The XpertMTB/RIF assay, CBNAAT assay is 
the rapid diagnostic test then. There is a sensitivity of around 60% 
among AFB-negative culture-positive cases and 97% among AFB-
positive cases.  
 
3.9 WHOM TO TEST? 
How the TB diagnosis should take place in India is guided by the 
standard tests by Revised National Tuberculosis Control of India (RNTCP). 
These standards were published in 2014 and describe the tests and protocol for 
the diagnosis of tuberculosis for all those patients who are suspected of 
tuberculosis including the special categories, like as those with tuberculosis and 
HIV co infection. 
Any person who has signs and symptoms suggestive of tuberculosis including 
 cough for more than 2 weeks  
  fever for more than 2 weeks 
 significant weight loss, loss of appetite 
 hemoptysis 
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 abnormality in chest x-ray with respiratory symptoms 
 Household contacts of pulmonary TB with respiratory symptoms. 
 
3.10 WHOM TO SCREEN? 
 People living with HIV (PLHIV/PLWHA) 
  people who are malnourished 
 People who have diabetes or cancer 
 People on steroid therapy 
 People on immune suppressive therapy. 
These populations should be regularly screened for signs and symptoms 
suggestive of tuberculosis. 
 
3.11 WHAT IS ENHANCED CASE FINDING? 
Having a high level of suspicion for tuberculosis in all medical 
encounters and then identifying or excluding tuberculosis using a combination 
of clinical questionnaires, radio graphical and simple microbiological testing. 
Enhanced case finding should be undertaken in certain high risk 
population groups like 
 healthcare workers 
  prisoners 
  slum dwellers  
  certain occupational groups such as mineworkers 
 Laboratory workers 
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3.12 DIAGNOSIS OF TUBERCULOSIS 
1. AFB MICROSCOPY 
2. NUCLEIC ACID AMPLIFICATION TECHNOLOGY 
3. MYCOBACTERIAL CULTURE 
4. RADIOGRAPHIC PROCEDURES 
5. DRUG SUSCEPTIBILITY TESTING 
6. ADDITIONAL DIAGNOSTIC PROCEDURES 
 
3.12.1. AFB MICROSCOPY 
The most reliable single method in diagnosis of Tuberculosis is sputum 
microscopy. Direct or concentrated smears are used normally. Its 
recommended to use new slides for every use, i.e. the slides should never be 
reused. It should be prepared from thick purulent part of sputum. They are 
dried and heat fixed and stained, to be examined under microscope. 
Zeihl-Neelson staining or fluorescent staining is used. If ZN staining, 
it’s viewed under oil immersion objective, under light microscope, the bacteria 
are seen as bright red rods. 
A minimum of 10,000 bacilli should be present in 1 milliliter of sputum 
for ready diagnosis by smear. To give a negative report, a minimum of 300 
fields should be examined. And a positive report is given if at least two typical 
bacilli are demonstrated. 
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Typical bacilli mean appearing barred or beaded, since saprophytes are stained 
uniformly. 
TABLE 1: ZN SMEAR EVALUATION AND AFB REPORT 
NO. OF AFB NO OF FIELDS REPORT 
0 300 NOT SEEN/NEGATIVE 
1-2 300 DOUBTFUL/REPEAT 
1-9 100 1+ 
1-9 10 2+ 
1-9 1 3+ 
10 OR MORE 1 4+ 
 
When large number of smears is diagnosed daily, fluorescent 
microscopy is better. The smears are stained with fluorescent stains and 
visualized under ultra violet illumination, and appear as bright rods in contrast 
to a dark background.LED microscopes are also available which are cheaper, 
and are as good as traditional fluorescent microscopes in sensitivity. 
 
ADVANTAGE OF MICROSCOPY 
 Cheap(3) 
 Maintenance cost is low 
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DISADVANTAGES 
 Time consuming 
 Inter observable variation 
 Less sensitive(3), poor positive predictive value.(3) 
 Saprophytes can be mistaken for true positives 
 Biosafety issues 
 Not much suitable for specimens other than sputum 
 HIV-TB confection, smear deviation rate is low 
 
3.12.2. NUCLEIC ACID AMPLIFICATION TECHNIQUES (8) 
This is based on the amplification of nucleic acids of the Mycobacterium 
Tuberculosis, so that, the specificity is high. 
 
ADVANTAGES 
 Less time consuming 
 Detection and Rifampicin resistance identified within 2-3 hours. 
 Minimal biosafety and training requirements.(7) 
 Sensitivity of 98% in AFB positive and 70% in AFB negative. 
 Can be housed in non-conventional laboratory settings(7) 
 
DISADVANTAGES 
 Cost effectively 
 Maintenance charges are relatively higher. 
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The  current WHO recommendation (14) is to use the nucleic acid 
amplification test as the initial diagnostic test in 
 suspected  MDR-TB adults and pediatrics 
 HIV-associated TB.  
 If resources available as a follow up test to smear positive TB 
 CSF from suspected TB meningitis 
 No respiratory specimens like gastric lavage, FNAC specimens, pleural 
biopsies etc. This test has a sensitivity of 98% 
 
3.12.3 CULTURE OF MYCOBACTERIA 
Definitive diagnosis of tuberculosis is based on culture or nucleic acid 
amplification. Specimens are cultured on egg or agar medium (e.g. Löwenstein 
– Jensen (LJ) or Middlebrook) and incubated at 37°C. As the Mycobacteria are 
slow growers, 4–8 weeks are required for growth to be detected.                             
M. tuberculosis is identified presumptively with growth time, pigmentation of 
colony, morphology and biochemical tests for speciating the isolates. In well-
equipped laboratories; liquid culture and molecular methods HPLC for 
isolation and species identification instead of solid culture and the biochemical 
tests. 
Fluorescent growth indicator tubes are available for the rapid 
identification of growth now a day. Immunochromatographic low cost antigen 
detection is also aiding in species identification. All these methods have limited 
the time needed for culture identification to be reduced to about 2-3 weeks. 
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So other main disadvantages are 
 Requirement of sophisticated laboratory 
 Cost 
 Time Consumption 
 
ADVANTAGES 
 gold standard for diagnosis 
 drug sensitivity possible simultaneously 
 
3.12.4 DRUG SUSCEPTIBILITY TESTING 
1. Direct on liquid medium-3 weeks 
2. Indirectly with culture isolates on solid or liquid media –about 8 weeks. 
3. Xpert  MTB/RIF assay detects Rifampin resistance 
4. Molecular line probe assays is available now for INH and Rifampicin 
5.  Microscopically observed drug susceptibility(MODS)-noncommercial, 
cheap 
6. Nitrate reductase assays -useful in resource poor scenarios 
 
3.12.5 RADIOLOGICAL DIAGNOSIS 
The initial suspicion of PTB is based on chest X-ray PA view. The 
classic picture is upper lobe disease with pulmonary infiltrates and cavities, but 
any radiographic pattern may be seen that is from normal film or solitary 
nodule or diffuse infiltrates are seen. In HIV-TB co infection, the chest X-ray 
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findings are not seen as the classical picture, more when the immunity is low. 
CT Chest is helpful with doubtful X-rays and Extra Pulmonary Tuberculosis 
like Pott’s spine. MRI, is useful for TB meningitis. 
 
3.12.6 SEROLOGICAL TESTS 
They are based on antibody detection to Mycobacterial antigens, mostly used in 
developing countries. Disadvantages include: 
 Not useful for diagnosis, especially with low probability of TB 
 Low sensitivity and specificity  
 Poor reproducibility(14) 
WHO issued  negative recommendation in 2011 for these tests even in 
resource poor settings(10). Determinations of ADA and IFN-γ in pleural fluids 
are considered as adjunctive tests in pleural TB, not recommended in other 
extra pulmonary tuberculosis. 
 
3.12.7 RNTCP LABORATORY NETWORKS 
A wide network of laboratories were established by RNTCP throughout 
India.TB tests can be done to diagnose people who have TB. These are 
primarily intended for  
 Proper diagnosis of TB with good sensitivity and specificity. 
 For the assessment and follow up of detected tuberculosis. 
 For the timely detection of drug resistance in TB patients. 
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The laboratory system includes: 
1. National Reference Laboratories or (NRLs) 
2.  State level Intermediate Reference Laboratories or (IRLs) 
3.  Culture & Drug Susceptibility Testing laboratories (C and DST 
laboratories)  
4. Designated Microscopy Centers or (DMCs). 
 
3.12.8 LED FLOURESCENT MICROSCOPY 
In traditional light microscopy using ZN technique, each of the smear 
examination may take an average of 5-10 minutes. These put high workloads 
for laboratories, and may consequently result in decreased reliability. 
Fluorescent microscopy (FM), was introduced as an alternative to light 
microscopy. The advantages over conventional microscopy includes, 
 10% more sensitive than ZN smear microscopy (12). 
  Fluorescent acid fast bacilli (AFB) can be seen at lower magnification, 
so they can be examined in lesser time compared to light microscopy. 
The time reduction is about 25%. 
  Can reduce the laboratory workloads. 
 
But the disadvantages include high cost and complexity of system as it 
is using mercury vapour lamps. There is a need for a dark room, and also health 
risks to laboratory workers due to exposure of ultraviolet rays are yet another 
concern. 
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Because of these technical difficulties, illumination systems based on 
Light emitting diodes (LED) were implemented. 
LED fluorescent microscopy holds several advantages over the 
conventional mercury vapour lamp fluorescent microscopy as well as the 
standard light microscopy. 
 Relatively inexpensive. 
 Have an effective lifespan of thousands of hours (13). 
 Easily manageable in terms of power supply, that is it can work even 
with power supply from batteries. 
 
Because of all these advantages LED fluorescent microscopy is more 
suitable for resource poor countries. 
One important concern is with specificity. Some of the studies showed 
that, LED fluorescent microscopy has higher sensitivity but lower specificity 
than ZN smear microscopy when compared to the gold standard, culture of 
Mycobacteria. 
 
3.13 XPERT MTB/RIF ASSAY/CBNAAT-IN AND OUT 
The Xpert MTB/RIF assay is a cartridge based nucleic acid 
amplification test, which is an automated test that can identify MTB DNA and 
resistance to Rifampicin (RIF) by nucleic acid amplification test or NAAT. It 
was developed by the laboratory of Professor David Alland at the University of 
Medicine and Dentistry of New Jersey.(17). 
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In December 2010, the world health organization endorsed the Xpert  
MTB/RIF assay in TB endemic countries.(2,15). 
Tuberculosis is still a deadly and fiery public health threat today, though 
it is considered as an age old disease developing along with mankind evolution.  
Tuberculosis is mostly diagnosed by chest X-rays, the microscopy with 
special stains, the growth in culture and the Mantoux test. The smear 
microscopy test has some problems in HIV positive patients, children and also 
in patients with low bacterial load. 
The Xpert MTB/RIF assay has high sensitivity & specificity for 
detection of pulmonary TB. An in vitro study demonstrated  detection of as 
small as 131 colony forming units(cfu) per ml , compared to about 10,000 cfu 
with conventional smear microscopy.(4). 
Susceptibility to drugs could only be diagnosed from the growth of 
MTB in culture which takes long time, about six weeks and needs high quality 
laboratories and cost. 
Drug susceptibility testing is highly relevant because tuberculosis is 
becoming increasingly resistant to two of the major antiTB drugs, INH and 
Rifampicin, which is called MDR TB, and it needs longer time and special 
drugs to treat. 
 
3.13.1 HOW IT WORKS? 
 The Xpert MTB/RIF assay purifies and concentrates Mycobacterium 
Bacilli from samples, isolates the genomic material from these captured 
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bacteria by sonication and then amplifies the genomic DNA by polymerase 
chain reaction (PCR). 
 This process also identifies all the clinically significant mutations in the 
RNA polymerase beta (rpoB) gene causing Rifampicin resistance in the 
Mycobacterium Tuberculosis genome in a real time process using fluorescent 
probes which are called the molecular beacons. 
Results are obtained roughly in about 90 minutes, with minimum 
biohazard and a very little technical training for operation. This can even be set 
up easily in a simple laboratory without much technical requirements. 
A review to assess the diagnostic accuracy of Xpert  MTB/RIF assay, 
found that when its used as an initial test without smear microscopy it had a 
pooled sensitivity of 89% and a specificity of 99%.However, when it was used  
for cases of negative smear microscopy the sensitivity was only 67% and 
specificity 99%.(19) 
In another clinical study, the sensitivity of the test on a single sputum 
sample was 92.2% for culture positive TB and 98.2% for both smear and 
culture positive patients and 72.5% for smear negative but culture positive 
cases, and there was a specificity of 99.2%. Sensitivity and specificity were 
slightly higher when three samples were tested.(5) 
CBNAAT was adopted in India by RNTCP in 2012. It first started as a 
pilot project in Maharashtra state, India. CBNAAT is currently available at 
more centers and the aim is to establish a link with all the peripheral hospitals 
to medical college hospitals and also implemented in private set up. 
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In our K.A.P.V Govt. medical college Trichy, Tamil Nadu, India CB-
NAAT started functioning since 2015 January. 
 
 
3.13.2 A NOTE ON DRUG RESISTANCE IN TUBERCULLOSIS 
Drug resistance usually occurs because of point mutations occurring in 
the genome of Mycobacterium Tuberculosis.  The Rifampicin resistance is 
associated with rpob gene mutation in 95% of cases. The resistance to 
Isoniazid, the mutations are mainly in the katG (50–95%) and inhA (up to 
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45%) of genes. For   Pyrazinamide resistance gene involved is the pncA gene 
(up to 98%) and  to Ethambutol it is embB gene (50–65%). For the second line 
drugs, for Fluoroquinolones mutation is in the gyrA–gyrB genes (75–95%) and 
for  Aminoglycosides mainly in the rrs gene (up to 80%). 
Because of these different gene involvement, there is no cross resistance 
among the commonly used drugs. The development of drug resistance in 
Tuberculosis is almost invariably as a result of monotherapy.  In addition, the 
usage  substandard quality drugs also can cause drug resistant Tuberculosis. 
Yet another, but the most important factor is patient compliance to treatment 
which has to be ensured for the prevention of a dreadful global burden- the 
drug resistant Tuberculosis. 
Drug resistant TB can be either primary or acquired. Primary drug 
resistance is that is present at the time of starting the treatment. Secondary drug 
resistance occurs during the treatment, that is initially patient will be 
responsive, but due to several afore mentioned reasons, resistance develops. 
 
 MDR TB: Multi Drug Resistant TB- Resistant to both Isoniazid  and 
Rifampicin 
 XDR TB: Extremely drug resistant TB- MDR strains with drug 
resistance to any of Flouroquinolones and to any of the three second line 
injectables like Amikacin, Kanamycin ,Capreomycin. 
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3.14 HIV/AIDS, PATHOGENESIS AND RELATION WITH 
TUBERCULOSIS 
HIV is the etiologic agent of AIDS, it belongs to Human Retrovirus 
family and the Lentivirus subfamily.(5)HAPTER 226 
The hallmark of HIV and AIDS is a florid immunodeficiency resulting 
from a progressive both qualitative and quantitative deficiency of the subset of 
T lymphocytes, the helper cells. This occurs in setting of polyclonal immune 
system activation. 
These Helper T cells are defined phenotypically by the presence of CD4 
molecule on its surface, which serves primarily as the cellular receptor for HIV. 
The major coreceptors are CCR5 and CXCR4,for fusion and entry to cells, also 
serve as the primary receptors for chemo attractive cytokines known as 
chemokines. 
The mechanisms responsible for cellular depletion and dysfunction of 
CD4 T cells include  
1. Direct infection and destruction by virus. 
2. Indirect effects like immune clearance, cell death associated with 
abnormal immune activation, immune exhaustion etc.  
 
 Approximately one third of all deaths in AIDS are associated with 
Tuberculosis and it is the primary cause of death in about 15% of patients with 
HIV. In India, prevalence is about 10% with HIV and active TB. Untreated TB 
will accelerate the course of HIV infection. 
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In contrast to infection with atypical mycobacteria, the active TB 
develops early in the course of HIV infection and can be considered as an early 
clinical sign of HIV disease. In one study, the median CD4 count at 
presentation of Tuberculosis was 326/µL.(8) The clinical manifestations of 
TBin HIV patients are quite varied and show difference in radiological 
presentation with difference in CD4. 
Patients with relatively high CD4+ T cell counts, there will be typical 
pattern of pulmonary reactivation that is they present with fever, cough, 
difficulty in breathing, weight loss, evening rise of temperature, and a chest x-
ray with upper lobe apical cavities. 
 In patients with lower CD4 T counts, disseminated diseases are more 
common and chest x-ray reveals diffuse or lower lobe bilateral infiltrates 
consistent with miliary spread, pleural effusions, or hilar prominence due to 
lymphadenopathy. 
Some patients may have no symptoms, and screening for TB should be a 
part of the initial evaluation of all patients with HIV infection. 
 
  
32 
 
CHAPTER - IV 
PREVIOUS STUDIES 
 
1) An observational study Pulmonary Medicine Maharajah’s Institute of 
Medical Sciences, Sowjanya et al, Vizianagaram 2012-2013. Out of 205 
sputum samples from HIV status unspecified patients, 108(52.68%) 
were ZN AFB smear positive, 96 (47.32%) were negative. In 
CBNAAT,144 (70.24%) were MTB positive and 61 (29.76%) negative.  
All results were statistically significant. The test also detected 4 RIF-
resistant specimens.(18). 
2) In another study, by Gerardo et al, in Badalapalli RDT hospital, 
Andhrapradesh, in 2011-12, shows that the CBNAAT assay can 
increase more than three times the rapid diagnosis of Extra Pulmonary 
Tuberculosis in HIV positive patients compared to LED ﬂuorescent 
microscopy.(7) 
3) Tortolli and colleague’s lab based study with eight nationally accredited 
laboratories in Italy. 268 of Extra Pulmonary Tuberculosis disease, 
compared with culture, the sensitivity and specificity of Xpert MTB/RIF 
assaywere 79.0% and 97.3% respectively.(20) 
4) Ligthelm et al  study showed excellent Xpert MTB/RIF assay  
sensitivity (96.7%) and specificity (86.6%) in patients with tuberculous 
lymphadenitis. (11) 
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5) Lawn and Zumla study showed a high sensitivity (81.3% for Extra 
Pulmonary Tuberculosis) of CBNAAT on a large number of non-
respiratory samples.(10) 
6) In another study, Boheme et al, conducted in patients from 5 sites in 
South Africa and Mumbai, India, patients suspecting pulmonary TB, 
HIV negative and positive were studied with sputum sample. The tests 
done were, AFB microscopy, ZN method, culture in LJ media and 
CBNAAT. Among culture positive PTB, the sensitivity of the 
CBNAAT was 97.6%.  For smear and culture positive patients, the 
sensitivity was 99.8, smear negative culture positive, it was 90.2%.(5) 
 
The sensitivity with CBNAAT was compared between HIV 
positive(98.4%)and negative individuals(93.9%),but there were no 
statistically significant co relation.(5) 
 
7) Study conducted by Avashiya et al in TB hospital Indore India from, 
Extra Pulmonary Tuberculosis lymphadenitis samples, cold abscess, 
CSF and pleural fluid were studied in HIV negative individuals.MTB 
was detected in 46 patients out of 81 (56.7%) pus samples, 24 of 103 
(23.3%) pleural fluid aspirates, and 15 of 45 (33.3%)CSF samples. The 
analysis revealed CBNAAT has true diagnostic potential in Extra 
Pulmonary Tuberculosis with good sensitivity.(2) 
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CHAPTER - V 
STATISTICS AND DISCUSSION 
 
A total of 130 patients were selected for thesis study. Out of these 80 
patients were suspected Pulmonary Tuberculosis patients, of which 40 were 
HIV positive and other 40 were HIV negative. 
 In rest of the patients, i.e. 50 patients was suspected Extra Pulmonary 
TB(EPTB) patients. Out of which 30 patients were suspected of tuberculous 
lymphadenitis and FNAC samples were taken from them. In this group also 15 
were HIV positive and other 15 were HIV negative. 
Out of 50 patients of Extra Pulmonary Tuberculosis, 20 patients were 
suspected of tuberculous pleural effusion and the sample taken was pleural 
fluid. Here also 10 were HIV positive and other 10 were HIV negative. 
In each group, age, sex, BMI were analyzed for any co relation between 
HIV positive and negative patients.HIV positive patients were categorized as 
pre ART patients, and patients on ART. Duration also was noted in months in 
each group. 
Age were categorized as 5 groups as less than 20yrs,20-30 years,30-40 
years,40-50 years and more than 50 years. 
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5.1 PULMONARY TUBERCULOSIS 
TABLE 2: CATEGORIZATION OF PTB SUSPECTING PATIENTS 
ACCORDING TO HIV STATUS 
PTB SUSPECTING PATIENTS 
NO.OF PATIENTS 
(n=80) 
PERCENTAGE 
(100%) 
HIV POSITIVE 40 50.0 
HIV NEGATIVE 40 50.0 
 
Out of 80 patients with suspicion of PTB selected for study,40 were 
HIV positive and 40 were HIV negative. 
 
5.1 A: AGE DISTRIBUTION 
Both these group of patients were stratified based on age groups into 5 
categories. The distribution of age in these groups were graphically represented 
as: 
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         When PTB suspecting HIV positive patients were stratified based on age, 
a majority of patients (37.5%) belongs to 41-50 years of age. And among PTB 
suspects of HIV negative patients the age distribution were higher with 
majority of about 50% were above the age of 50 years. 
Chi square test was applied to these two groups to compare and analyses 
the difference. 
2.50%
15.00%
25.00%
37.50%
15.00%
5.00%
CHART 1-AGE DISTRIBUTION: SUSPECTED 
PTB,HIV POSITIVE
Below 20yrs 21 to 30yrs 31 to 40yrs
41 to 50yrs 51 to 60yrs 61yrs & above
27.50%
10.00%
22.50%
10.00%
17.50%
12.50%
CHART 2 AGE DISTRIBUTION: SUSPECTED 
PTB,HIV NEGATIVE
Below 20yrs 21 to 30yrs 31 to 40yrs
41 to 50yrs 51 to 60yrs 61yrs & above
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TABLE 3: AGE DISTRIBUTION AMONG PTB SUSPECTS,BASED ON 
HIV STATUS 
AGE 
Pulmonary TB 
suspecting (HIV 
+ve) 
Pulmonary TB 
suspecting(HIV-ve) 
Total Statistical 
inference 
n % n % n % 
Below 
20yrs 
1 2.5% 11 27.5% 12 15.0% 
X
2
=16.517 
Df=5 
.006<0.05 
Significant 
21 to 
30yrs 
6 15.0% 4 10.0% 10 12.5% 
31 to 
40yrs 
10 25.0% 9 22.5% 19 23.8% 
41 to 
50yrs 
15 37.5% 4 10.0% 19 23.8% 
51 to 
60yrs 
6 15.0% 7 17.5% 13 16.3% 
61yrs & 
above 
2 5.0% 5 12.5% 7 8.8% 
Total 40 100.0% 40 100.0% 80 100.0% 
 
CONCLUSION 
The majority of patients suspecting of pulmonary tuberculosis in HIV 
positive based on chest X ray and clinical findings were in a lower age group 
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when compared to HIV negative patients when analyzed with Chi square 
testing using SPSS software. 
 
5.1B: SEX DISTRIBUTION 
 
 
Among PTB suspecting patients with HIV positivity, 15 out of 40(37.5%) were 
females, 25 out of 40 patients(62.5%) were males. 
62.50%
37.50%
CHART 3 : SEX DISTRIBUTION PTB SUSPECTS HIV 
POSITIVE
MALE FEMALE
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Among PTB suspects with HIV negativity,13 out of 40 patients(32.5%) 
were females, 27 out of 40 (67.5%) were males. 
That is, there was an increased number of male patients in PTB suspects 
for HIV negative patients when compared to HIV positive patients. This was 
analysed using Chi square test and found statistically insignificant. 
  
67.50%
32.50%
CHART 4:SEX DISTRIBUTION PULMONARY TB SUSPECTS 
HIV NEGATIVE
MALE FEMALE
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TABLE 4:  SEX DISTRIBUTION AMONG PTB SUSPECTS, BASED ON 
HIV STATUS 
SEX 
Pulmonary TB 
suspecting (HIV +ve) 
Pulmonary TB 
suspecting  
(HIV-ve) 
Total Statistical 
inference 
n % n % n % 
Male 25 62.5% 27 67.5% 52 65.0% X
2
=.220 
Df=1 
.639>0.05 
Not 
Significant 
Female 15 37.5% 13 32.5% 28 35.0% 
Total 40 100.0% 40 100.0% 80 100.0% 
 
CONCLUSION 
There is no statistically significant co relation between suspected PTB 
patients who are HIV positive and HIV negative based on sex distribution, 
when analysed using Chi square test SPSS software. 
 
5.1C: BMI DISTRIBUTION 
Mean BMI of the study group was 19. So BMI was categorized as two 
groups, BMI <19 and >19.Among HIV positive, BMI <19 were predominant, 
28 out of 40 patients(70%),and HIV negative group, BMI >19 were 
predominant, 27 out of 40 patients(67.5%) 
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TABLE 5: BMI DISTRIBUTION AMONG PTB SUSPECTING 
PATIENTS, BASED ON HIV STATUS 
BMI 
PTB 
SUSPECTING 
(HIV +ve) 
PTB 
SUSPECTING 
(HIV-ve) 
Total Statistical 
inference 
n % n % n % 
Below 
19 
28 70.0% 13 32.5% 41 51.3% X
2
=11.257 
Df=1 
.001<0.05 
Significant 
Above 
19 
12 30.0% 27 67.5% 39 48.8% 
Total 40 100.0% 40 100.0% 80 100.0% 
70%
30%
32.50%
67.50%
0%
10%
20%
30%
40%
50%
60%
70%
80%
Below 19 Above 19
CHART 5:BMI DISTRIBUTION IN PTB SUSPECTS,HIV 
POSITIVE AND NEGATIVE
PTB SUSPECTED HIV +VE PTB SUSPECTED HIV -VE
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CONCLUSION 
Mean BMI was 18.39 with a standard deviation of 2.35 among PTB 
suspecting HIV positive patients and it was 20.95 and 1.54 respectively in HIV 
negative patients. 
There was statistically significant co relation with the finding that the 
patients suspecting PTB among HIV negative individuals have a higher BMI 
than HIV positive, when analyzed using Chi square testing, SPSS software. 
 
5.1D: DETECTION WITH FLUORESCENT LED MICROSCOPY 
When LED fluorescent microscopy test was used to detect the 
pulmonary TB suspected, ZN smear negative patients in 40 HIV positive 
patients, the results were obtained as32 out of 40 patients( 80% ) were  AFB 
negative, 6 out of 40(15%) were AFB 1+ and 2 patients of 40( 5%) were AFB 
2+. 
When the same method was applied in HIV negative patients with 
suspected PTB, the results were,31 patients out of 40 (77.5% ) was of AFB 
negative, 3 patients(7.5% ) were of AFB 1+,3 patients out of 40(7.5% ) were 
AFB 2+ and the last 7.5% were AFB3+. 
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15.00%
5.00%
0%
80.00%
CHART 6: DETECTION WITH LED MICROSCOPY IN PTB 
SUSPECTING HIV(+)
AFB 1+ AFB 2+ AFB 3+ AFB NEGATIVE
7.50%
7.50%
7.50%
77.50%
CHART 7: DETECTION WITH LED MICROSCOPY IN PTB 
SUSPECTING HIV (-)
AFB 1+ AFB 2+ AFB 3+ AFB NEGATIVE
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TABLE 6:  DETECTION OF PTB WITH FLOURESCENT LED 
MICROSCOPY, BASED ON HIV STATUS 
FLOURESCENT 
LED 
MICROSCOPY 
RESULTS 
HIV 
POSITIVE 
HIV 
NEGATIVE 
Total 
Statistical 
inference 
n % n % n % 
AFB 1+ 6 15.0% 3 7.5% 9 11.3% X
2
=4.216 
Df=3 
.239>0.05 
Not 
Significant 
AFB 2+ 2 5.0% 3 7.5% 5 6.3% 
AFB 3+ 0 0% 3 7.5% 3 3.8% 
NEG 32 80.0% 31 77.5% 63 78.8% 
Total 40 100.0% 40 100.0% 80 100.0% 
 
CONCLUSION 
The increased detection of PTB with LED fluorescent microscopy in 
HIV negative patients when compared to HIV positive patients were 
statistically insignificant when Chi square test was applied using SPSS 
software. 
The results with fluorescent LED microscopy were categorized as AFB 
positive and AFB negative.AFB positive includes all patients detected as AFB 
1+,AFB 2+ and AFB 3+ and the rest as negative. 
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The detection of PTB in ZN smear negative PTB suspects by LED 
fluorescent microscopy was,9 out of 40( 22.5%) patients among HIV positive 
patients and 8 out of 40( 20%) among HIV negative patients. So there is a 
seemingly better detection with LED fluorescent microscopy among HIV 
negative patients. 
  
80.00%
77.50%
20.00%
22.50%
0.00% 10.00%20.00%30.00%40.00%50.00%60.00%70.00%80.00%90.00%
PTB SUSPECTING HIV (+)
PTB SUSPECTING HIV (-)
CHART 8: DETECTION OF PTB SUSPECTS BY LED 
MICROSCOPY,HIV(+)&(-)
LED AFB POSITIVE LED AFB NEGATIVE
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TABLE 7:  DETECTION OF PTB WITH FLOURESCENT LED 
MICROSCOPY, BASED ON HIV STATUS 
 
LED 
FLOURESCEN
T 
MICROSCOPY 
AFB 
PULMONAR
Y TB 
SUSPECTIN
G HIV(+) 
PULMONAR
Y TB 
SUSPECTIN
G HIV(-) 
Total 
Statistica
l 
inference 
n % n % n % 
Negative 32 80.0% 31 77.5% 
6
3 
78.8% 
X
2
=0.075 
Df=1 
.785>0.05 
Not 
Significan
t 
Positive 8 20.0% 9 22.5% 
1
7 
21.3% 
Total 40 100.0% 40 100.0% 
8
0 
100.0
% 
 
CONCLUSION 
 The increased detection of PTB with LED fluorescent microscopy in 
HIV negative patients when compared to HIV positive patients were 
statistically insignificant when Chi square test was applied using SPSS 
software 
 
  
47 
 
5.1E: DETECTION WITH CBNAAT 
When CBNAAT was used to detect the PTB in sputum samples of ZN 
smear negative patients with HIV(n=40) and without HIV(n=40),CBNAAT 
was positive in 21 HIV positive and 28 HIV negative patients. That is, among 
HIV positive patients the detection of PTB was 48% using CBNAAT.(52% 
were negative).In HIV negative patients CBNAAT detected 70% patients as 
positive and 30% as negative. The seemingly increased detection with 
CBNAAT in HIV negative patients were analyzed against HIV positive. 
 
 
In HIV negative patients, CBNAAT detected in 28 out of 40 patients( 
70%) of pulmonary TB and in HIV positive patients, the detection was 21 out 
of 40 patients.( 52.5%.) So there is a seemingly better detection of PTB with 
CBNAAT among HIV negative patients, and was analyzed statistically. 
47.50%
30.00%
52.50%
70.00%
0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 80.00%
PTB SUSPECTING HIV(+)
PTB SUSPECTING HIV (-)
CHART 9: COMPARISON OF DETECTION BY CBNAAT,PTB 
SUSPECTS,HIV(+)&HIV(-)
CBNAAT POSITIVE CBNAAT NEGATIVE
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TABLE 8:  DETECTION OF PTB WITH CBNAAT, BASED ON HIV 
STATUS 
CBNAAT 
PTB 
SUSPECTING 
HIV (+VE) 
PTB 
SUSPECTING 
HIV(-) 
Total Statistical 
inference 
n % n % n % 
Negative 19 47.5% 12 30.0% 31 38.8% X
2
=2.581 
Df=1 
.108>0.05 
Not 
Significant 
Positive 21 52.5% 28 70.0% 49 61.3% 
Total 40 100.0% 40 100.0% 80 100.0% 
 
CONCLUSION 
The increased detection of PTB with CBNAAT in HIV negative patients 
when compared to HIV positive patients was statistically insignificant when 
Chi square test was applied using SPSS software. 
This is in accordance with the study done by Boheme et al.(5) 
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5.1F:  DETECTION OF RIFAMPICIN RESISTANCE WITH CBNAAT: 
Out of the CBNAAT positive patients of both the groups, Rifampicin 
resistance was detected for three patients. One was an HIV positive patient and 
other 2 were HIV negative. 
 
TABLE 9: DETECTION OF RIFAMPICIN RESISTANCE OF PTB  
WITH CBNAAT, BASED ON HIV STATUS 
RIFAMPICIN 
RESISTANCE 
HIV 
POSITIVE 
HIV 
NEGATIVE 
Total Statistical 
inference 
n % n % n % 
NA 19 47.5% 12 30.0% 31 38.8% X
2
=2.697 
Df=2 
.260>0.05 
Not 
Significant 
Detected 1 2.5% 2 5.0% 3 3.8% 
Not detected 20 50.0% 26 65.0% 46 57.5% 
Total 40 100.0% 40 100.0% 80 100.0% 
 
CONCLUSION 
There was no statistically significant co relation in the detection of 
Rifampicin resistance by CBNAAT in PTB, HIV positive and negative groups 
when analyzed with Chi square testis’s software. 
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5.1G: DETECTION OF ZN SMEAR NEGATIVE PTB IN HIV 
PATIENTS AND NON HIV PATIENTS GROUP, COMPARISON 
BETWEEN CB NAAT AND FLOURESCENT LED MICROSCOPY: 
 
Based on the LED microscopy results and CBNAAT results, all the patients 
were grouped as  
1. FLOURESCENT LED MICROSCOPY POSITIVE,CBNAAT 
POSITIVE (M +ve & CB+ve) 
2. FLOURESCENT LED MICROSCOPY NEGATIVE,CBNAAT 
POSITIVE(M-ve & CB+ve) 
3. FLOURESCENT LED MICROSCOPY AND CB NAAT 
NEGATIVE(M –ve & CB -ve) 
 
In HIV positive patients, LED fluorescent microscopy positive and CB 
NAAT positivity were 8 were, LED fluorescent microscopy positive and CB 
NAAT negative patients were 13 and LED fluorescent microscopy negative 
and CB NAAT negativity were 19. 
In HIV negative, these were 9,18 and13 patients respectively. So a 
difference were noted in these two groups with higher fluorescent LED 
microscopy smear negative PTB detection with CBNAAT in HIV negative 
patients compared to HIV positive. 
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HIV POSITIVE 
 
 
 
LED fluorescent microscopy was positive in 8 out of 21 patients( 
38.1%),and all of them were CB NAAT positive. CB NAAT detected 13 out of 
21 (61.9%) of ZN negative PTB patients. All CB NAAT negative patients were 
also fluorescent AFB negative. 
 
PTB SUSPECTING HIV POSITIVE PATIENTS = 40 
FLOURESCENT MICROSCOPY AFB * CBNAAT  
  
61.90%
100%
38.10%
0
0.00% 20.00% 40.00% 60.00% 80.00% 100.00% 120.00%
CBNAAT POSITIVE
CB NAAT NEGATIVE
CHART 10: COMPARISON OF DETECTION WITH LED 
FLOURESCENT MICROSCOPY AND CBNAAT IN HIV 
POSITIVE PTB 
AFB POSITIVE AFB NEGATIVE
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TABLE 10:  COMPARISON OF PTB DETECTION BY LED 
FLUORESCENT MICROSCOPY AND CBNAAT AMONG HIV 
POSITIVE PATIENTS 
 
LED MICROSCOPY 
AFB 
CBNAAT DETECTION 
Statistical 
inference 
Negative Positive Total 
n % n % n % 
Negative 19 100% 13 61.9% 32 80.0% 
X
2
=9.048 df=1 
.003<0.05 
Significant 
Positive 0 0 8 38.1% 8 20% 
Total 19 100% 21 100% 40 100% 
 
CONCLUSION 
There was a better detection of PTB with CBNAAT when compared to 
Fluorescent LED microscopy in ZN smear negative PTB in HIV positive 
patients. This was statistically significant when analyzed with Chi square 
testing using SPSS software. 
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HIV NEGATIVE 
 
 
 
All of the patients detected by light microscopy were CBNAAT 
positive. But out of the total patients detected by CBNAAT, only 32.1% were 
AFB positive. So there seems to be a better detection with CBNAAT when 
compared to AFB detection by LED fluorescent microscopy. 
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CHART 11: COMPARISON OF DETECTION BY 
FLOURESCENT LED MICROSCOPE AND CBNAAT IN HIV 
NEGATIVE PTB
CBNAAT NEGATIVE CBNAAT POSITIVE
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5.1H DETECTION OF ZN SMEAR NEGATIVE PTB IN HIV PATIENTS 
AND NON HIV PATIENTS, COMPARISON BETWEEN CB NAAT AND 
FLOURESCENT LED MICROSCOPY 
 
 
  
20%
32.50%
47.50%
22.50%
45%
32.50%
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CHART 12: COMPARISON OF OUTCOME BY LED 
MICROSCOPY AND CBNAAT IN PTB SUSPECTING HIV 
POSITIVE AND NEGATIVE PATIENTS
PTB SUSPECTS HIV POSITIVE PTB SUSPECTS HIV NEGATIVE
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TABLE 11: COMPARISON OF OUTCOME OF DETECTION WITH 
FLUORESCENT LED MICROSCOPY AND CBNAAT WITH HIV 
STATUS OF PATIENTS 
 
Outcome 
PULMONARY TB SUSPECTING 
PATIENTS Statistical 
inference (HIV +ve) (HIV-ve) Total 
N % n % n % 
M+ve& CB 
+ve 
8 20% 9 22.5% 17 21.3% 
X
2
=1.990 df=2 
.370>0.05 
Not Significant 
M -ve& CB 
+ve 
13 32.5% 18 45% 31 38.8% 
M-ve& CB -
ve 
19 47.5% 13 32.5% 32 40% 
Total 40 100% 40 100% 80 100% 
 
CONCLUSION 
 There was no statistically significant co relation in HIV positive and 
HIV negative patients with the outcome of fluorescent LED microscopy and 
CBNAAT detection in suspected PTB, when analyzed with Chi square testing 
using SPSS software. 
This was in accordance with the studies conducted by Boheme et al.(5) 
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5.2 EXTRA PULMONARY TUBERCULOSIS 
A total of 50 Extra Pulmonary Tuberculosis patients were included in 
the study. Out of this,30 were FNAC specimens from suspected tuberculosis 
lymphadenitis, of which 15 were HIV positive, and 15 HIV negative. 
The rest 20 specimens were pleural fluid aspirates. Out of which 10 
were from HIV positive individuals and 10 from HIV negative. 
They were also subjected to LED microscopy analysis, and CBNAAT. 
 
5.2.1DETECTION WITH FLUORESCENT LED MICROSCOPY OF 
FNAC SPECIMEN OF TB LYMPHADENITIS 
The detection with Fluorescent LED microscopy in 15 HIV positive individuals 
in FNAC specimen were, 
AFB 1+ were 2 
AFB 2+ were 2 
AFB 3+ was 1 and AFB negative were 10 out of 15 patients. 
In HIV negative, AFB 1+ were 5 patients, AFB 2+ was 1 patient out of 
15(6.70%),AFB 3+ were 1 out of 15(6.7%) and AFB negative were 8 
patients(53.3%) 
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CHART 13:DETECTION OF TUBERCULOUS LYMPHADENITIS 
WITH LED FLOURESCENT MICROSCOPY IN HIV POSITIVE
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WITH LED FLOURESCENT MICROSCOPY IN HIV NEGATIVE
AFB 1+ AFB 2+ AFB 3+ NEG
58 
 
DETECTION OF TUBERCULOUS LYMPHADENITIS WITH 
FLOURESCENT LED MICROSCOPY, BASED ON HIV STATUS 
 
 
 
Tuberculous lymphadenitis detection among HIV negative patients was 
46%, and among HIV positive patients, it was 33%. 
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AFB POSITIVE AFB NEGATIVE
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TABLE 12:  DETECTION OF TUBERCULOUS LYMPHADENITIS 
WITH FLOURESCENT LED MICROSCOPY, BASED ON HIV STATUS 
MICROSCOPY 
AFB 
FNAC 
(HIV+) 
FNAC  
(HIV-) 
Total Statistical 
inference 
n % n % n % 
1+ 2 13.3% 5 33.3% 7 23.3% 
X
2
=1.841 Df=3 
.606>0.05 
Not Significant 
2+ 2 13.3% 1 6.7% 3 10.0% 
3+ 1 6.7% 1 6.7% 2 6.7% 
NEG 10 66.7% 8 53.3% 18 60.0% 
Total 15 100.0% 15 100.0% 30 100.0% 
 
CONCLUSION 
There was no statistically significant co relation in HIV positive and 
HIV negative patients with the detection of Tuberculous lymphadenitis with 
LED fluorescent microscopy, when analyzed with Chi square testing using 
SPSS software. 
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5.2.2 DETECTION WITH CBNAAT OF FNAC SPECIMEN, TB 
LYMPHADENITIS 
 
TABLE 13:  DETECTION OF TUBERCULOUSLYMPHADENITIS 
WITH FLOURESCENT LED MICROSCOPY, BASED ON HIV STATUS 
CBNAAT 
POSITIVE 
TYPE 
FNAC 
(HIV+) 
FNAC 
(HIV-) 
Total Statistical 
inference 
n % n % n % 
Negative 4 26.7% 6 40.0% 10 33.3% X
2
=0.600 
Df=1 
.439>0.05 
Not 
Significant 
Positive 11 73.3% 9 60.0% 20 66.7% 
Total 15 100.0% 15 100.0% 30 100.0% 
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CB NAAT showed a positive result of 11 out of 15 patients (73.3%) in 
HIV positive patients and 9 out of 15 patients (60%) in HIV negative patients 
in detection of tuberculosis lymphadenitis. 
 
CONCLUSION 
There was no statistically significant difference  in HIV positive and 
HIV negative patients with the detection of tuberculous lymphadenitis with 
LED fluorescent microscopy, when analysed with Chi square testing using 
SPSS software. 
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5.2.3 COMPARISON BETWEEN CBNAAT AND LED MICROSCOPY 
RESULTS IN TUBERCULOUS LYMPHADENITIS 
 
 Out of 15 patients of HIV positive suspecting tuberculosis 
lymphadenitis, Fluorescent LED microscopy was compared to CBNAAT 
results. 
 
TABLE 14:  COMPARISON OF TUBERCULOUS LYMPHADENITIS 
DETECTION BY LED FLUORESCENT MICROSCOPY AND CBNAAT 
AMONG HIV POSITIVE PATIENTS 
 
Out of 15 specimens, 
LED fluorescent microscopy negative and CB NAAT negative were 4 
LED fluorescent microscopy negative and CB NAAT positive were 5 
LED fluorescent microscopy negative CBNAAT positive were 6 
Statistical analysis between the results were done using Chi square test. 
 
FLOURESCENT LED 
MICROSCOPY  
CBNAAT  RESULT 
Statistical 
inference 
Negative Positive Total 
n % N % n % 
Negative 4 100% 6 54.5% 10 66.7% 
X
2
=2.727 df=1 
.099>0.05 
Not Significant 
Positive 0 0 5 45.5% 5 33.3% 
Total 4 100% 11 100% 15 100% 
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CONCLUSION 
There was no statistically significant difference between the detection of 
tuberculosis lymphadenitis using CB NAAT and fluorescent LED microscopy 
among HIV positive patients. This was against the tests quoted. Probably 
because of low sample size. 
 
 
 
Chart shows that, all the CBNAAT negative patients were AFB   
negative. Among CB NAAT positivity,8 out of 15(54.5% )were AFB negative 
and 7 out of 15( 45.5% )were AFB positive. 
 
HIV NEGATIVE PATIENTS 
100%
0
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CHART 19: COMPARISON OF CBNAAT AND LED AFB 
RESULTS IN TUBERCULOUS LYMPHADENITIS IN HIV 
POSITIVE
CB NAAT NEGATIVE CBNAAT POSITIVE
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In the other group of HIV negative patients, with suspecting tuberculous 
lymphadenitis, 
 
LED fluorescent microscopy negative and CB NAAT negative were 6 
LED fluorescent microscopy negative and CB NAAT positive were 2 
LED fluorescent microscopy negative and CBNAAT positive were 7 
 
 
 
Chart shows that, all the CB NAAT negative patients were AFB 
negative. Out of the CB NAAT positive patients, 7 out of 9 patients(77.8%) 
were AFB positive and 2 out of 15 patients 22.2% were AFB negative. 
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TABLE 15:  COMPARISON OF TUBERCULOUS LYMPHADENITIS 
DETECTION BY LED FLUORESCENT MICROSCOPY AND CBNAAT 
AMONG HIV NEGATIVE PATIENTS 
 
LED FLOURESCENT 
MICROSCOPY AFB 
CBNAAT RESULT 
Statistical 
inference 
Negative Positive Total 
n % n % n % 
 AFB NEGATIVE 6 100% 2 22.2% 8 53.3% X
2
=8.750 
df=1 
.003<0.05 
Significant 
AFB POSITIVE 0 0 7 77.8% 7 46.7% 
Total 6 100% 9 100% 15 100% 
 
CONCLUSION 
There is statistically significant better detection with CBNAAT 
compared to LED microscopy, in patients who are HIV negative with 
tuberculous lymphadenitis.(13),analyzed with Chi square test,SPSS software. 
 
PLEURAL FLUID 
20 patients were analysed in this group. 10 were HIV positive and 10 
were HIV negative. 
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5.2.4 FLOURESCENT LED DETECTION OF TB PLEURAL EFFUSION 
In HIV positive patients LED microscopy detected 9 out of 10(90%) 
samples as AFB negative and 1 out of 10(10%) patients as AFB 1+ positive. 
In HIV negative patients, this was 8 out of 10(80%) negative and two of 
10(20%)  patients were AFB 1+ that is, scanty positivity. 
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AFB 1+ AFB NEGATIVE
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TABLE 16:  DETECTION OF TUBERCULOUS PLEURAL EFFUSION 
WITH  FLOURESCENT LED MICROSCOPY, BASED ON HIV 
STATUS 
FLOURESCENT 
LED 
MICROSCOPY 
AFB 
PF (HIV+) PF (HIV-) Total 
Statistical 
inference n % n % n % 
1+ 1 10.0% 2 20.0% 3 15.0% X
2
=0.392 
Df=1 
.531>0.05 
Not 
Significant 
NEG 9 90.0% 8 80.0% 17 85.0% 
Total 10 100.0% 10 100.0% 20 100.0% 
 
CONCLUSION 
There is no statistically significant difference in detection of tuberculous 
pleural effusion with LED microscopy between HIV positive and negative 
patients, using Chi square test, SPSS software. 
 
5.2.5 CB NAAT DETECTION OF TB PLEURAL EFFUSION 
Of the 10 pleural fluid samples from HIV positive patients, 8 out of 10 
(80%) were CBNAAT negative and 2 out of 10 patients,(20%) were CBNAAT 
positive. 
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In HIV negative patients, CBNAAT was positive in 3 out of 10 
patients(30%) samples and 7 out of 10(70%) were CBNAAT negative. 
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TABLE 17:  DETECTION OF TUBERCULOUS PLEURAL EFFUSION 
WITH CB NAAT, BASED ON HIV STATUS 
 
CBNAAT 
RESULT 
PLEURAL 
FLUID (HIV+) 
PLEURAL 
FLUID (HIV-) 
Total Statistical 
inference 
n % n % n % 
Negative 8 80.0% 7 70.0% 15 75.0% X
2
=0.267 
Df=1 
.606>0.05 
Not 
Significant 
Positive 2 20.0% 3 30.0% 5 25.0% 
Total 10 100.0% 10 100.0% 20 100.0% 
 
CONCLUSION 
There is no statistically significant better detection of TB pleural 
effusion in HIV negative individuals, when compared to HIV positive, when 
analyzed with Chi square test, using SPSS software. 
 
5.2.6 COMPARISON OF DETECTION BETWEEN LED 
FLOURESCENT MICROSCOPY AND CB NAAT  
HIV POSITIVE: 
Out of 15 specimens, 
 LED fluorescent microscopy negative and CB NAAT negative were 8 
 LED fluorescent microscopy positive and CB NAAT  positive were 1 
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 LED fluorescent microscopy negative and CB NAAT positive  were 1 
 
Chart shows that all the AFB positive patients were CB NAAT positive. 
Out of all the CB NAAT positive patients,7 out of 9, (77.8%) were AFB 
positive,2 out of 9(22.2% )were AFB negative 
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TABLE 18:  COMPARISON OF TUBERCULOUS PLEURAL 
EFFUSION DETECTION BY LED FLUORESCENT MICROSCOPY 
AND CBNAAT AMONG HIV POSITIVE PATIENTS 
LED 
FLOURESCENT 
MICROSCOPY 
AFB 
CBNAAT POSITIVE TYPE 
Statistical 
inference 
Negative Positive Total 
n % n % n % 
Negative 8 100% 1 50% 9 90% X
2
=4.444 
df=1 
.035<0.05 
Significant 
Positive 0 0 1 50% 1 50% 
Total 8 100% 2 100% 10 100% 
 
CONCLUSION 
There is s statistically significant better detection with CB NAAT when 
compared to fluorescent LED microscopy in tuberculous pleural effusion in 
HIV positive patients. 
HIV NEGATIVE 
Total number of patients:10 
 LED fluorescent microscopy negative and CB NAAT negative were 
7(70%) 
 LED fluorescent microscopy positive and CB NAAT positive were 
2(20%) 
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 LED fluorescent microscopy negative and CB NAAT positive were 
1(10%) 
 
Chart shows that, all CB NAAT negative patients were AFB negative. Out 
of CB NAAT positivity,1 out of 10(10%) was AFB positive. And 1 out of 10 
(10%) was AFB negative. 
 
TABLE 19:  COMPARISON OF TUBERCULOUS PLEURAL 
EFFUSION DETECTION BY LED FLUORESCENT MICROSCOPY 
AND CBNAAT AMONG HIV NEGATIVE PATIENTS 
FLOURESCENT LED 
MICROSCOPY AFB 
CBNAAT RESULT 
Statistical 
inference 
Negative Positive Total 
n % n % n % 
Negative 7 100% 1 33.3% 8 80% X
2
=5.833 
df=1 
.016<0.05 
Significant 
Positive 0 0 2 66.7% 2 20% 
Total 7 100% 3 100% 10 100% 
 
CONCLUSION 
There is s statistically significant better detection with CB NAAT when 
compared to fluorescent LED microscopy in tuberculous pleural effusion in 
HIV negative patients. 
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5.2.7 COMPARISON OF OUTCOME OF EXTRA PULMONARY 
TUBERCULOSIS DETECTION WITH CBNAAT AND LED 
MICROSCOPY: 
 
TABLE 20: COMPARISON OF OUTCOME OF DETECTION OF 
EXTRA PULMONARY TUBERCULOSIS WITH FLUORESCENT LED 
MICROSCOPY AND CBNAAT WITH HIV STATUS OF PATIENTS 
 
Outcome 
EXTRA PULMONARY TB  
Statistical inference HIV +ve HIV-ve Total 
n % n % n % 
M +ve& 
CB +ve 
6 24% 9 36% 15 30% 
X
2
=2.240 df=2 
.326>0.05 
Not Significant 
M -ve& 
CB +ve 
7 28% 3 12% 10 20% 
M-ve& 
CB -ve 
12 48% 13 52% 25 50% 
Total 25 100% 25 100% 50 100% 
 
CONCLUSION 
In Extra Pulmonary Tuberculosis, the results of two tests CBNAAT and 
LED fluorescence microscopy were not having statistically significant 
difference in HIV positive and negative patients when  analysed with Chi 
square test, SPSS software. 
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5.2.8 COMPARISON OF OUTCOME WITH CBNAAT AND LED 
MICROSCOPY WITH CD4 COUNT: 
 
TABLE 21: COMPARISON OF OUTCOME OF DETECTION WITH 
FLUORESCENT LED MICROSCOPY AND CBNAAT WITH CD4 
COUNT OF PATIENTS WITH HIV. 
 
CD4 
COUNT 
Outcome of LED flourescent microscopy & CB 
NAAT 
Statistical 
inference 
M+ve& 
CB +ve 
M -ve& 
CB +ve 
M-ve& CB 
-ve 
 
Total 
n % n % n % n % 
Below 
100 
4 28.6% 5 25% 5 16.1% 14 21.5% 
X
2
=5.137 
df=6 
.526>0.05 
Not 
Significant 
101 to 
350 
6 42.9% 13 65.0% 21 67.7% 40 61.5% 
351 to 
500 
1 7.1% 1 5.0% 3 9.7% 5 7.7% 
500 & 
above 
3 21.4% 1 5.0% 2 6.5% 6 9.2% 
Total 14 100% 20 100% 31 100% 65 100% 
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One-way ANOVA 
CD4 
COUNT 
Mean S.D SS DF MS 
Statistical 
inference 
Between 
Groups 
  224813.746 2 112406.873 
F=2.109 
.130>0.05 
Not 
Significant 
M +ve& CB 
+ve (n=14) 
355.64 358.009    
M -ve& CB 
+ve (n=20) 
215.50 239.130    
M-ve& CB –
ve (n=31) 
210.84 135.562    
Within 
Groups 
  3304006.408 62 53290.426 
 
Here the CD4 counts were analyzed in these 3 groups of both LED 
microscopy and CBNAAT positivity, LED microscopy negative and CB 
NAAT positive and both the tests negative groups. Mean CD4 in both positive 
were 355.64 with ,In both negative group were 210.84 and LED microscopy 
negative and CBNAAT positive were 215.50.This also was found to be not 
statistically significant. 
 
CONCLUSION 
There was no statistically significant co relation with the CD4 count and 
methods of detecting tuberculosis in PLWHA when analyzed with Chi square 
and ANNOVA test using SPSS software. 
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CHAPTER- VI 
CONCLUSION 
 
1. The majority of Pulmonary tuberculosis suspects in HIV positive based 
on chest X ray and clinical findings were in a  lower age group when 
compared to HIV negative patients when analyzed with chi square 
testing. 
2. There is no statistically significant co relation between suspected PTB 
patients who are HIV positive and HIV negative based on sex 
distribution, when analyzed using Chi square test. 
3. Mean BMI was 18.39 with a standard deviation of 2.35 among PTB 
suspecting HIV positive patients and it was 20.95 and 1.54 respectively 
in HIV negative patients. There was statistically significant co relation 
with the finding that the patients suspecting PTB among HIV negative 
individuals have a higher BMI than HIV positive, when analyzed using 
Chi square testing. 
4. The increased detection of PTB with LED fluorescent microscopy in 
HIV negative patients when compared to HIV positive patients were 
statistically insignificant when Chi square test was applied using SPSS 
software. 
5. :The increased detection of PTB with CBNAAT in HIV negative 
patients when compared to HIV positive patients were statistically 
insignificant when Chi square test was applied using SPSS software. 
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6.  There was no statistically significant co relation in the detection of 
Rifampicin resistance by CBNAAT in PTB,HIV positive and negative 
groups when analysed with Chi square test,SPSS software 
7. There was a better detection with CBNAAT when compared to 
fluorescent LED microscopy in ZN smear negative PTB in HIV positive 
patients. This was statistically significant when analysed with Chi 
square testing using SPSS software 
8. There was no statistically significant co relation in HIV positive and 
HIV negative patients with the outcome of fluorescent LED microscopy 
and CBNAAT detection in suspected PTB, when analyzed with Chi 
square testing using SPSS software. 
This was in accordance with the studies conducted by Boheme et al.(5) 
9. There was no statistically significant co relation in HIV positive and 
HIV negative patients with the detection of Tuberculous lymphadenitis 
with LED fluorescent microscopy, when analyzed with Chi square 
testing using SPSS software. 
10. There was no statistically significant difference  in HIV positive and 
HIV negative patients with the detection of tuberculous lymphadenitis 
with LED fluorescent microscopy, when analysed with Chi square 
testing using SPSS software. 
11. There was no statistically significant difference between the detection of 
tuberculosis lymphadenitis using CB NAAT and fluorescent LED 
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microscopy among HIV positive patients. This was against the tests 
quoted. Probably because of low sample size. 
12. There is statistically significant better detection with CBNAAT 
compared to LED microscopy, in patients who are HIV negative with 
tuberculous lymphadenitis.(13),analyzed with Chi square test,SPSS 
software 
13. There is no statistically significant difference in detection of tuberculous 
pleural effusion with LED microscopy between HIV positive and 
negative patients, using Chi square test, SPSS software. 
14. There is no statistically significant better detection of TB pleural 
effusion in HIV negative individuals, when compared to HIV positive, 
when analyzed with Chi square test, using SPSS software. 
15. There is s statistically significant better detection with CB NAAT when 
compared to fluorescent LED microscopy in tuberculous pleural 
effusion in HIV positive patients. 
16. There is s statistically significant better detection with CB NAAT when 
compared to fluorescent LED microscopy in tuberculous pleural 
effusion in HIV negative patients. 
17. In Extra Pulmonary Tuberculosis, the results of two tests CBNAAT and 
LED fluorescence microscopy were not having statistically significant 
difference in HIV positive and negative patients when  analysed with 
Chi square test, SPSS software. 
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18. There was no statistically significant co relation with the CD4 count and 
methods of detecting tuberculosis in PLWHA when analyzed with Chi 
square and ANNOVA test using SPSS software. 
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CHAPTER - VII 
LIMITATIONS OF STUDY 
 
1. Low sample size,( total 130,pulmonary tuberculosis-80, extra 
pulmonary tuberculosis-50) 
2. Smaller duration of study (January 2015-April 2016) 
3. Inadequate specimen varieties in extra pulmonary tuberculosis 
4. Detection was not confirmed with the gold standard of detection, 
culture of Mycobacterium Tuberculosis 
5. Rifampicin resistance not confirmed with line probe assay or 
culture 
6. All the patients who were HIV negative were arbitrarily taken as 
having normal CD 4 count. 
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PROFORMA 
 
NAME  : 
AGE   :                                 ID NO : 
WEIGHT :                                 HEIGHT :                      BMI : 
SEX  :  
HIV STATUS: POSITIVE/NEGATIVE 
POSITIVE  : ART /PRE ART 
DURATION : 
PULMONARY TB/EXTRA PULMONARY TB: 
IF EXTRA PULMONARY    : FNAC/PF 
CXR FINDINGS     : PRESENT/ABSENT 
AFB POSITIVE/NEGATIVE 
POSITIVE  :  
CBNAAT-  HIGH     /     MEDIUM      /     LOW     /VERY LOW 
RIFAMPICIN RESISTANCE       DETECTED     /   NOT DETECTED 
CD4 COUNT : 
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Nehahsp xg;Gjy; gbtk; 
ehd; ___________________________ kfhj;kh fhe;jp muR 
epidT kUj;Jtkidapy;  khuilg;Gf;F rpfpr;ir ngw;W 
tUfpNwd;.  ,e;j kUj;jtkidpapy; eilngWk; Ma;thd 
“fhrNeha; fz;lwptjw;fhd  rpgp ehl; kw;Wk; Ez; ghpNrhjid” 
nra;;tjw;F kUj;Jth; %yk; vdJ nrhe;j nkhopapy; 
mwpe;Jnfhz;Nld;. ,jpy; gq;Nfw;Wf;nfhs;s vdJ 
RaepidTld; rk;kjk; mspf;fpNwd;.   
 
 
,lk; :        ifnahg;gk; 
ehs; :  
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Nehahsp jfty; jhs; 
Nehahspapd; ngah;  :  
taJ    :  
ghypdk;    : 
fy;tpj; jFjp   :  
Ntiy    :  
NehAw;w fhyk;   : 
Nehapd; jd;ik   :  
cldhsh; ngah;   :  
cwT    :  
cldhshpd; fy;tpj; jFjp :  
cldhshpd;; Ntiy  :  
ehd; ___________________________ kfhj;kh fhe;jp muR 
epidT kUj;Jtkidapy;  khuilg;Gf;F rpfpr;ir ngw;W 
tUfpNwd;.  ,e;j kUj;jtkidpapy; eilngWk; Ma;thd 
“fhrNeha; fz;lwptjw;fhd  rpgp ehl; kw;Wk; Ez; ghpNrhjid”  
gw;wp kUj;Jth; %yk; vdJ nrhe;j nkhopapy; 
mwpe;Jnfhz;Nld;. ,jpy; gq;Nfw;Wf;nfhs;s vdJ 
RaepidTld; rk;kjk; mspf;fpNwd;.   
 
,lk; :       ifnahg;gk; 
ehs; :  
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ABBREVIATIONS 
AFB  : ACID FAST BACILLI 
AIDS            :           ACQUIRED IMMUNO DEFECIENCY SYNDROME 
ART  : ANTI RETRO VIRAL THERAPY 
ATT  : ANTI TUBERCULOUS THERAPY 
BMI               :           BODY MASS INDEX 
CBNAAT : CATRIDGE BASED NUCLEIC ACID AMPLIFICATION  
  TEST 
CD 4  : CLUSTER OF DIFFERENTIATION 
CFU               : COLONY FORMING UNIT 
CMI  : CELL MEDIATED IMMUNITY 
CNS  : CENTRAL NERVOUS SYSTEM 
CT  : COMPUTERISED TOMOGRAPHY 
EPTB  : EXTRA PULMONARY TUBERCULOSIS 
FNAC  : FINE NEEDLE ASPIRATION CYTOLOGY 
HIV               : HUMAN IMMUNO DEFICIENCY VIRUS 
IL  : INTERLEUKIN 
INH                : ISONIAZID  
LED  : LIGHT EMITTING DIODE 
MDR  : MULTI DRUG RESISTANT 
MRI  : MAGNETIC RESONANCE IMAGING 
MTB  : MYCOBACTERIUM TUBERCULOSIS 
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MTB/RIF : MYCOBACTERIUM TUBERCULOSIS/RIFAMPICIN  
   RESISTANCE 
PA view : POSTERO ANTERIOR 
PLWHA : PERSONS LIVING WITH HIV AND AIDS 
PTB  : PULMONARY TUBERCULOSIS 
RIF                : RIFAMPICIN  
RNTCP        : REVISED NATIONAL TUBERCULOSIS CONTROL  
   PROGRAM 
rpoB             : RNA POLYMERASE B 
SPSS  : STATISTICAL PRACTICE IN SOCIAL SCIENCES 
TB  : TUBERCULOSIS 
TH 1  : T HELPER CELLS 
TNF  : TUMOUR NECROSIS FACTOR 
TST  : TUBERCULIN SENSITIVITY TEST 
XDR TB : XTREMELY DRUG RESISTANT TUBERCULOSIS 
ZN  : ZEIHL NEELSON 
 
 
 
